(A1)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

G00002

(43) International Publication Date
13 June 2002 (13.06.2002)

PCT

(10) International Publication Number
WO 02/045753 A3

(51) International Patent Classification[7]: A61K 31/506, 9/22

(21) International Application Number: PCT/EP01/14189

(22) International Filing Date:
30 November 2001 (30.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00204388.3 8 December 2000 (08.12.2000) EP

(71) Applicant: **AKZO NOBEL N.V.** [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL).

(72) Inventors: **EGBERINK, Johannes, Gerardus, Joseph**; N.V. Organon, Postbus 20, NL-5340 BH Oss (NL). **ENGELHART, John, Francis**; Organon Inc., 375 Mt.Pleasant Ave, West Orange, NJ 07092 (US).

(74) Agent: **KRAAK, Hajo**; P.O. Box 20, NL-5340 BH Oss (NL).

(81) Designated States *(national)*: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZA.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(88) Date of publication of the international search report:
29 August 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/045753 A3

162162

(54) Title: ORAL EXTENDED RELEASE FORMULATION OF GEPIRONE

(57) Abstract: This invention makes a pharmaceutical formulation for oral administration with extended release properties available comprising an amount of gepirone hydrochloride, an amount of a cellulosic polymer matrix and an amount of microcrystalline cellulose characterised in that the amount the pharmaceutically acceptable cellulosic polymer matrix is from 70 to 85 wt%, the amount of carbohydrate binder is from 7 to 10 wt% and the amount of gepirone hydrochloride is from 13 to 21 wt%. The formulation is useful for a treatment for depression or a related central nervous system disorder with gepirone administered in a once-a-day oral formulation for extended release of gepirone.